title: Proof of concept for low-dose molecular breast imaging with a dual-head CZT gamma camera. Part I. Evaluation in phantoms.
abstract: OBJECTIVE
  Molecular breast imaging (MBI) is a nuclear medicine technology that uses dual-head cadmium zinc telluride (CZT) gamma cameras to image functional uptake of a radiotracer, Tc-99m sestamibi, in the breast. An important factor in adoption of MBI in the screening setting is reduction of the necessary administered dose of Tc-99m sestamibi from the typically used dose of 740 MBq to approximately 148 MBq, such that MBI's whole-body effective dose is comparable to that of screening mammography. Methods that increase MBI count sensitivity may allow a proportional reduction in the necessary administered dose. Our objective was to evaluate the impact of two count sensitivity improvement methods on image quality by evaluating count sensitivity, spatial resolution, and lesion contrast in phantom simulations.
  
  
  METHODS
  Two dual-head CZT-based MBI systems were studied: LumaGem and Discovery NM 750b. Two count sensitivity improvement methods were implemented: registered collimators optimized for dedicated breast imaging and widened energy acceptance window optimized for use with CZT. System sensitivity, spatial resolution, and tumor contrast-to-noise ratio (CNR) were measured comparing standard collimation and energy window setting [126-154 keV (+10%, -10%)] with optimal collimation and a wide energy window [110-154 keV (+10%, -21%)].
  
  
  RESULTS
  Compared to the standard collimator designs and energy windows for these two systems, use of registered optimized collimation and wide energy window increased system sensitivity by a factor of 2.8-3.6. Spatial resolution decreased slightly for both systems with new collimation. At 3 cm from the collimator face, LumaGem's spatial resolution was 4.8 and 5.6 mm with standard and optimized collimation; Discovery NM 750b's spatial resolution was 4.4 and 4.6 mm with standard and optimized collimation, respectively. For both systems, at tumor depths of 1 and 3 cm, use of optimized collimation and wide energy window significantly improved CNR compared to standard settings for tumors 8.0 and 9.2 mm in diameter. At the closer depth of 1 cm, optimized collimation and wide energy window also significantly improved CNR for 5.9 mm tumors on Discovery NM 750b.
  
  
  CONCLUSIONS
  Registered optimized collimation and wide energy window yield a substantial gain in count sensitivity and measurable gain in CNR, with some loss in spatial resolution compared to the standard collimator designs and energy windows used on these two systems. At low-count densities calculated to represent doses of 148 MBq, this tradeoff results in adequate count density and lesion contrast for detection of lesions ≥8 mm in the middle of a typical breast (3 cm deep) and lesions ≥6 mm close to the collimator (1 cm deep).
authors: Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. hruska.carrie@mayo.edu
authors: Carrie B
authors: CB
authors: Hruska
authors: Amanda L
authors: AL
authors: Weinmann
authors: Michael K
authors: MK
authors: O'Connor
mesh_terms: D001940:Breast / Q000000981:diagnostic imaging*; D002104:Cadmium; D015902:Gamma Cameras; D019047:Phantoms, Imaging; D011829:Radiation Dosage; D011877:Radionuclide Imaging / Q000295:instrumentation*; D059629:Signal-To-Noise Ratio; D013691:Tellurium; D015032:Zinc
chemical_list: C474490:CdZnTe; D002104:Cadmium; D015032:Zinc; D013691:Tellurium